These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37596961)

  • 1. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
    Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
    Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A; Smith JS; Larocca C
    J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract]   [Full Text] [Related]  

  • 3. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
    Joshi TP; Duvic M
    J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
    Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
    Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of CD8-positive Sézary syndrome from mycosis fungoides following dupilumab treatment.
    Fujii K; Yoshizaki A; Matsuoka A; Baba N; Ohshima K; Kanekura T
    Eur J Dermatol; 2024 Jun; 34(3):294-296. PubMed ID: 39015963
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art therapy of mycosis fungoides and Sézary syndrome.
    Kemme DJ; Bunn PA
    Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
    Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
    Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of amitriptyline in mycosis fungoides.
    Coe P
    Palliat Med; 1999 May; 13(3):264. PubMed ID: 10474718
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
    Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
    Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
    [No Abstract]   [Full Text] [Related]  

  • 12. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome.
    Papps T; McCormack C; Buelens O; Van der Weyden C; Twigger R; Campbell BA; Dickinson M; Prince HM
    Br J Dermatol; 2020 Feb; 182(2):497-498. PubMed ID: 31512229
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
    Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
    Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
    [No Abstract]   [Full Text] [Related]  

  • 16. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
    Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
    [No Abstract]   [Full Text] [Related]  

  • 17. Is blocking IL-4 receptor alpha beneficial for patients with mycosis fungoides or Sézary syndrome?
    Sugaya M
    J Dermatol; 2021 May; 48(5):e225-e226. PubMed ID: 33651394
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin in combination with low-dose methotrexate in advanced-stage mycosis fungoides and Sézary syndrome.
    Cieza-Díaz DE; Machan S; Prieto-Torres L; Requena L; Córdoba R
    Dermatol Ther; 2021 May; 34(3):e14952. PubMed ID: 33724662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.